Large-cap Health Care company Illumina has moved -2.3% so far today on a volume of 1,095,689, compared to its average of 1,563,669. In contrast, the S&P 500 index moved -1.0%.
Illumina trades -31.0% away from its average analyst target price of $213.06 per share. The 18 analysts following the stock have set target prices ranging from $125.0 to $318.0, and on average have given Illumina a rating of hold.
If you are considering an investment in ILMN, you'll want to know the following:
-
Illumina has moved -26.0% over the last year, and the S&P 500 logged a change of 16.0%
-
Based on its trailing earnings per share of -26.56, Illumina has a trailing 12 month Price to Earnings (P/E) ratio of -5.5 while the S&P 500 average is 15.97
-
ILMN has a forward P/E ratio of 63.4 based on its forward 12 month price to earnings (EPS) of $2.32 per share
-
The company has a price to earnings growth (PEG) ratio of -27.69 — a number near or below 1 signifying that Illumina is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 3.54 compared to its sector average of 4.16
-
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function.
-
Based in San Diego, the company has 11,500 full time employees and a market cap of $23.27 Billion.